Hans Biomed Corp 042520

KRX · South Korea · Health Services

KRW 21,200.00-1,350.00 (-5.99%)

Market closed· Oct 2, 2026, 5:46 AM UTC· KRW · Data may be delayed

Prices may be delayed and are for informational purposes only - not investment advice.

Hans Biomed Corp 042520

KRX · South Korea · Health Services

KRW 21,200.00-1,350.00 (-5.99%)

Market closed· Oct 2, 2026, 5:46 AM UTC· KRW · Data may be delayed

Prices may be delayed and are for informational purposes only - not investment advice.

-42.55% · 6MFull-screen chart

Open KRW 22,700.00High KRW 22,700.00Low KRW 21,100.00Close KRW 21,200.00Volume 68.71K

Oct 2, 2026

Charts by TradingView Lightweight Charts

Key statistics

Previous close: KRW 22,550.00
Day range: KRW 21,100.00 – KRW 22,700.00
52-week range: KRW 15,300.00 – KRW 57,800.00
Volume: 68.71K
Market cap: KRW 284.73B
Next earnings date: 2026-12-17
Avg. volume (1Y): 348.22K

Performance

1 week

+20.49%

1 month

+9.05%

3 months

-2.69%

6 months

-34.34%

Year to date

-18.11%

1 year

+1.40%

Total return, dividends included.

Company profile

Sector: Health Services
Industry: Medical/Nursing Services
Country: South Korea
Exchange: KRX
Shares outstanding: 14.26M
Employees: 289
ISIN: KR7042520007
Beta: 0.95

Technical view

Mixed

Where the price sits against its 50- and 200-day moving averages.

Valuation & analysis

Makkler Fair Value, financial health score, analyst view, peers and MakklerAI.

News

Yahoo FinanceApr 01, 2026

Hugel to enter ECM-based injectable market with aesthetic portfolio expansion

Hugel Inc., a leading global medical aesthetics company publicly traded in South Korea, has accelerated its growth strategy by adding an extracellular matrix (ECM)-based injectable treatment to its portfolio.

Recent third-party headlines about this company, kept separate from Makkler's own editorial coverage and linking out to the publisher. Accuracy is the publisher's responsibility.